Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.

By 3 months, those on exenatide had a mean reduction of − 7.7 monthly headache days (from a baseline of ~ 22 days/month) compared to a −1.5 day change in the placebo arm, although the between-group difference did not reach statistical significance (exenatide: p = 0.069 within-group; placebo: p = 0.404).

also in 111,027 other papers

In the “IIH: Pressure” RCT, both exenatide and placebo groups had normal baseline acuity; there was a slight trend toward better acuity in the exenatide arm at 3 months (mean improvement ~ 0.08 logMAR vs. baseline, p = 0.07) [ 14 ].

also in 4,078 other papers